Edition:
United States

Key Developments: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

4.78USD
3:27pm EDT
Change (% chg)

$-0.04 (-0.73%)
Prev Close
$4.82
Open
$4.83
Day's High
$4.83
Day's Low
$4.69
Volume
66,776
Avg. Vol
425,369
52-wk High
$58.00
52-wk Low
$4.37

Latest Key Developments (Source: Significant Developments)

Chimerix Q1 loss per share $0.57
Monday, 9 May 2016 07:30am EDT 

Chimerix Inc : Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results . Q1 loss per share $0.57 . Q1 revenue $1.2 million . Q1 revenue view $2.8 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Inc presents positive results from brincidofovir pivotal study in animal model for smallpox
Monday, 8 Feb 2016 02:03pm EST 

Chimerix Inc:Presents positive results from brincidofovir pivotal study in animal model for smallpox.Study met its primary endpoint of clinically and statistically significant (p<0.05) reduction in mortality for brincidofovir-treated animals compared with animals that received placebo.Final data from the rabbitpox study together with efficacy data from a mouse model of smallpox will be submitted to the FDA for discussion of next steps.  Full Article

Chimerix Inc announces top-line results from Phase 3 SUPPRESS Trial of Brincidofovir
Monday, 28 Dec 2015 07:30am EST 

Chimerix Inc:Announces top-line results from phase 3 suppress trial of brincidofovir.Says primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm.Says plans to continue the programs testing brincidofovir in serious adenovirus infections and in smallpox.Primary endpoint failures in prevention of cmv infections, mortality in brincidofovir ARM driven by confirmed cases of GVHD.Says non-statistically significant increase in mortality in the brincidofovir arm compared to the control arm.Chimerix has elected to pause further enrollment in the phase 3 sustain and surpass trials in kidney transplant recipients.Says SUPPRESS did not achieve primary endpoint for prevention of clinically significant CMV infection after HCT.  Full Article

Chimerix initiates Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients
Thursday, 22 Oct 2015 04:02pm EDT 

Chimerix Inc:Initiates Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.Topline data from SUPPRESS are anticipated in early 2016.  Full Article

Chimerix and BARDA announces contract extension of $13.0 million
Monday, 14 Sep 2015 08:00am EDT 

Chimerix, Inc:Announced extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of the broad spectrum antiviral, brincidofovir, as a medical countermeasure to treat smallpox.Latest contract extension provides an additional $13.0 million to Chimerix for a period of 15 months.  Full Article

Chimerix Inc announces exercise in full of option to purchase additional shares of common stock
Tuesday, 16 Jun 2015 08:00am EDT 

Chimerix Inc:Says the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 566,250 shares of its common stock at the public offering price of $39.75 per share, less customary underwriting discounts and commissions.As a result, the total number of shares being sold in the offering is 4,341,250 shares.The closing of the sale of all the shares in the offering is expected to occur on June 16.Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.Morgan Stanley and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, and Cowen and Company, LLC, Barclays Capital Inc., Piper Jaffray & Co., Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C. are acting as co-managers for the offering.  Full Article

Chimerix Inc announces issue of shares-Form 8-K
Thursday, 11 Jun 2015 04:10pm EDT 

Chimerix Inc:Entered into an underwriting agreement with Morgan Stanley & Co LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein relating to the issuance and sale of 3,775,000 shares of its common stock, par value $0.001 per share.The price to the public in this offering is $39.75 per share, and the underwriters have agreed to purchase the shares from the company, pursuant to the underwriting agreement, at a price of $37.365 per share.The net proceeds to the company from this offering are expected to be about $140.6 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the company.The offering is expected to close on or about June 16.In addition, under the terms of the underwriting agreement, the company has granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 566,250 shares of common stock to cover over-allotments, if any.  Full Article

Chimerix Inc prices public offering of common stock
Wednesday, 10 Jun 2015 07:14pm EDT 

Chimerix Inc:Says pricing of underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $39.75 per share.Gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be about $150 million.Says offering is expected to close on or about June 16.Anticipates using net proceeds from offering to fund its research and development efforts and for general corporate purposes, including working capital.Says Morgan Stanley and J.P. Morgan Securities LLC are acting as joint book-running managers for offering.And Cowen and Company, LLC, Barclays Capital Inc., Piper Jaffray & Co., Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C. are acting as co-managers for offering.Says Chimerix has granted the underwriters a 30-day option to purchase up to an aggregate of 566,250 additional shares of common stock.  Full Article

Chimerix announces commencement of public offering of common stock
Tuesday, 9 Jun 2015 04:31pm EDT 

Chimerix Inc:Intends to offer and sell, subject to market and other conditions, about $150.0 million of its common stock in an underwritten public offering.Anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.  Full Article

Chimerix Inc and ContraVir Pharmaceuticals establish strategic collaboration for antiviral drug candidate CMX157
Thursday, 18 Dec 2014 06:00am EST 

Chimerix Inc and ContraVir Pharmaceuticals, Inc:Says that they have entered into a strategic collaboration for the further clinical development and commercialization of CMX157.CMX157 is a potent analog of the antiviral drug tenofovir DF (Viread).Says ContraVir licenses CMX157 from Chimerix in exchange for an upfront payment consisting of 120,000 shares of ContraVir preferred stock with a stated value of $1.2 mln.Says in addition, Chimerix is eligible to receive up to about $20 mln in clinical, regulatory and initial commercial milestones in the United States and Europe, as well as royalties and additional milestones based on commercial sales in those territories.  Full Article

BRIEF-Chimerix Q1 loss per share $0.57

* Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results